Gemtuzumab Ozogamicin
Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Organ Dysfunctions
... Keywords: acute myeloid leukemia; patients with organ dysfunction; gemtuzumab ozogamicin.. 26 27.[r] ...
8
Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
... patients. Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal antibody that was approved by the US Food and Drug Administration for use as monotherapy in patients 60 years of age and older with relapsed ...
10
The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia
... Abstract: Through the years gemtuzumab ozogamicin (GO) has moved from a panacea in the treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of targeted therapy with ...
8
Reinduction Chemotherapy with Gemtuzumab Ozogamicin and Intermediate/High Dose Cytarabine: A Single Center Experience
... with gemtuzumab ozogamicin (GO) plus cytarabine as a salvage regimen (GO reinduction) for pa- tients who did not achieve complete remission (CR) after the first cycle of induction chemotherapy or at first ...
8
Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
... Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EO[r] ...
13
Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
... VOD as seen with gemtuzumab ozogamicin has been re- ported with the use of INO in the setting of autologous or allogeneic transplant [55–57, 59, 63, 73, 85]. A retrospect- ive study of 26 patients with ...
9
Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia
... Our integrated approach to measure the immunogen- icity of InO consisted of an assessment of pertinent factors affecting the immunogenicity risk coupled with crafting a robust bioanalytical strategy to assess the ...
14
Mylotarg has potent anti leukaemic effect : a systematic review and meta analysis of anti CD33 antibody treatment in acute myeloid leukaemia
... Despite advances in supportive care, the outcome of patients with acute myeloid leukaemia (AML) remains poor with only about 40 % of adults under 60 years of age achieving long- term survival, and in those over 60 years ...
14
Drug induced veno occlusive disease of the liver : unravelling the role of the inflammatory and coagulation pathways
... Structure of Gemtuzumab Ozogamicin CD33 expression in THPl cells CD33 expression in HepG2 cells TH Pl Cytokine Secretion Levels after Treatment with Mylotarg HepG2 Cytokine Secretion Lev[r] ...
155
The Development of Personalized Medicine: Acute Myeloid Leukemia as a Model
... The studies on novel therapeutic targets, including surface antigen, driver oncogenes and cellular pathways have been an active field of AML research in recent years. Thus, there are many pathway specific agents and ...
12
NOVEL RP HPLC AND UV METHOD DEVELOPMENT AND VALIDATION FOR INOTUZUMAB OZOGAMICIN IN BULK AND ITS PHARMACEUTICAL DOSAGE FORM
... Inotuzumab ozogamicin in bulk and its pharmaceutical dosage ...Inotuzumab ozogamicin in the injection dosage ...Inotuzumab Ozogamicin was shown in ...
7
Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
... inotuzumab ozogamicin with some of the current standard-of-care regimens for the treatment of B-cell malig- nancies or replacing components of chemotherapy regimens with inotuzumab ozogamicin is a potential ...
8
Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
... Inotuzumab ozogamicin is a CD22 monoclonal antibody conjugated to the cytotoxic antibiotic ...inotuzumab ozogamicin was tested in Phase 1/2 and Phase 3 clinical trials and it demonstrated improved complete ...
8
Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
... The relapse rate remains high after chemotherapy for adult patients with acute lymphoblastic leukemia (ALL). With better molecular diagnosis and classification as well as better assessment for minimal residual disease, ...
13
Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
... inotuzumab ozogamicin/CD22 receptor complex takes ...inotuzumab ozogamicin-containing endosome with a lysosome, resulting in a lower internal pH of the vesicle, subsequent degradation of the acid labile ...
8